lost in pennyland
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You guys should cut Bob some slack or issue a phony PR in his name about a BUGS contract with BP. Just sayin'...
Anyone check out the balance sheet on the 10Q? Can anyone find me a better looking balance sheet for a five cent stock? Or any stock trading below a dollar while we're at it?
It's best you sell here and buy 'em back at an 80% discount - if you're still interested then.
Interesting, the bid is now higher than the ask. Somebody wants in...
I'll look into that further this weekend. Meantime, from the 10K I figured out that the OS is actually about 100 million higher than the 380 million figure.
It's more like 480 million.
The 10K states that the Quercus trust owns 39% of the shares outstanding, which would leave about 230 million shares. So the float is no more than 230 million, but it trades even smaller.
Today's volume is considered heavy at just under 500,000.
I think we will start seeing revenues within a year. If the technology has improved like they believe it has, profits too.
Looks like this trades below a million shares a day almost all the time. For a 380 million-plus OS, that volume seems really low. Are most of the shares tied up by insiders, or are most free trading?
Upgraded ENSL to a sure thing.
ah I think me and ameritrade missed that 2500 to 1 reverse split. I see all of that trading at .0001, but after I read your post I checked pinksheets. Thanks.
You're right. There are probably a hundred opportunities like that every year, maybe more. It only takes one...
I want to puke after looking at that chart. I'm going to go down a bottle of aquaprin. Another stock I could have retired on if I would have been paying attention to at the right time.
One of these days...
Great article Crude, thanks. You get the feeling that if anybody is going to push solar to become the leader in energy production, it's David Gelbaum. I'm more confident in ENSL's chances after reading that story. It looks like he wouldn't release a product until the calculus adds up to a profit.
Oh yeah I remember you were in BFRE a while back. So he's really become obsessed with solar but he hasn't found the winning technology yet. I think everyone has written off solar for now. We'll see over the next year if ENSL's new products can compete.
Here's a proven winner in pennyland. I didn't know anything about this guy when I invested in ENSL. WOWSA.
http://articles.sfgate.com/2004-11-07/bay-area/17455002_1_carona-wilderness-yosemite-national-park
Highest volume since May '10. Starting to get interesting here...
So in essence, SOEN and ENSL are two divisions of the same company. I always linked these two together because they're both solar, but I didn't realize that they were majority owned by the same trust.
Good points. We should be finding out shortly about whether their move to this new technology is going to pay off, right? They're expected to start selling the new products this quarter. It looks like to me that these products are going to give ENSL a competitive advantage not only over other solar products, but (and this is the important hurdle) other energy alternatives.
I'm personally making a big gamble on this myself, so I'm cringing as I've watched the stock fall about 30% over the last two days.
ENSL - Bullish 8K today...The CEO just announced his purchase of $200,000 worth of shares for his family trust. The company is to begin selling their new generation solar products in Q2 2011.
http://www.sec.gov/Archives/edgar/data/811271/000092963811000302/form8k.htm
Bullish 8k out today. The CEO just announced his purchase of $200,000 worth of shares through his family trust. He's buying on the shares with his family trust instead of giving himself shares like most CEOs do. This is a huge vote of confidence in the technology.
http://www.sec.gov/Archives/edgar/data/811271/000092963811000302/form8k.htm
You make a great case to get out now. In fact, looking at it from your point of view, I still see .0001 in the cards.
Thanks Rain. It'll be interesting to see where they feel they're at after this steep rise and fall in their stock price.
I think mine is broke too.
which indicators are you using?
What are the chances that this new technology will be profitable?
WOW there you go, cypath saw a false positive rate of 42%, CT scans show up to 33% false positives. Already not that far from par.
That says it all Rain. Get a much cheaper and completely safe test on par (or better) with CTs at diagnosing cancer, and you have another epogen.
Epogen made one trick pony Amgen the largest biotech in the world about 15 years ago with a market cap somewhere in the range of 60 billion dollars.
That's the huge advantage Biomoda has with cypath. Absolutely no side effects from use. Get the test to par or close to a CT scan and cypath will be a blockbuster product.
I'm optimistic they'll get it done. The trick is to make it cost effective for everyone. I believe they'll eventually succeed.
Oh yes I agree completely. If cypath becomes a standard cancer screen around the world for just lung cancer this would be worth 20 billion. It's the if part that is always the most dIFficult.
Ah, ok. So there are no current plans to increase the share count. What do you think, is there perhaps 50 million shares of dilution coming before they get through phase III?
Added CTNO to the list of longshot winners. Added SRSP and FRMC to the list of mistakes.
Added ENSL and BMOD to the list of longshots.
two things you're wrong about. The specificity was 58% not 53%. Secondly, the next step would not be surgery, it would be a confirmatory cat scan.
I agree, as I mentioned in an earlier post, that this would lead to a lot of unnecessary CTs, which the insurance companies will want no part of.
I'm curious what the specificity of the pap test is/was. Biomoda can and should sacrifice sensitivity to get the specificity to 100%.
Better to have 40% sensitivity and 100% specificty than the current numbers. Ideally, of course, the automation will improve both.
I'm unclear on that too. Apparently Dr. Bauer will be coming out with a paper that fully explains the results, so hopefully he will break down the numbers so that it makes sense.
could you provide a link for the German financing? TIA
That's a terrific analysis. I'll take 5x my investment over the next year to year and a half - and I think they're being prudently conservative.
Thanks for the link.
Just hold tight guys. Might get some real bargains over the next couple of months.
Always fun when a stock goes radioactive like this one. We have a very interesting player driving this stock around it appears.
Somebody sparked it with a huge sell yesterday morning. Then a lot of other people played follow the leader without really understanding the news.